You are here: Industry Insights > ALS

News List

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Designation for Riluzole Oral Soluble Film to T biospace
February 01, 2018
FDA announced today that the U.S. Food and Drug Administration (FDA) has granted orphan riluzole oral soluble film (riluzole OSF) for the treatment of amyotrophic lateral sclerosis (ALS) Drug name
Cytokinetics’ ALS treatment tirasemtiv fails to meet primary endpoint in phase 3 study pharmaceutical-business
November 24, 2017
Cytokinetics has announced that international phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS) has did not meet the primary endpoint.
Cytokinetics cans lead drug after phase 3 ALS wipeout fiercebiotech
November 22, 2017
Researchers set out to learn whether tirasemtiv, a fast skeletal muscle troponin activator, could drive greater improvements on a measure of lung capacity than placebo over 24 weeks. Tirasemtiv failed to clear that bar.
Mitsubhishi Tanabe Pharma's ALS drug treats more than 1000 people in three months biospectrumasia
November 20, 2017
Radicava is the second drug approved to treat ALS in 22 years
Verge Genomics joins special departments at top four universities to boost research in ALS biospectrumasia
October 09, 2017
The objective of this collaboration is to find ways to synthesize these technologies by generating integrated, large-scale genomic, imaging, and biological datasets that can bridge the gap between findings derived from patients and preclinical models of A
Payers line up to back Mitsubishi Tanabe's pricey new ALS therapy Radicava fiercepharma
August 17, 2017
Mitsubishi Tanabe Pharma America's Radicava is the second-ever FDA-approved ALS med.
New target could yield treatment for Alzheimer's, ALS and more fiercebiotech
August 17, 2017
Researchers led by Genentech have discovered a new drug target for neurodegenerative diseases.
RNA-targeting CRISPR could yield treatments for Huntington's, ALS fiercebiotech
August 11, 2017
UC San Diego researchers are using CRISPR-Cas9 to target RNA, which could lead treatments for genetic diseases that have no cure.
First FDA-Approved Treatment for ALS in 22 Years Now Available In U.S. americanpharmaceuticalreview
August 09, 2017
Mitsubishi Tanabe Pharma America announced RADICAVA (edaravone) is now available for treatment in the United States.
MT Pharma America's Radicava secures FDA approval to treat ALS pharmaceutical-technology
May 10, 2017
MT Pharma America has secured the US Food and Drug Administration (FDA) approval for Radicava (edaravone) as an intravenous infusion treatment for patients affected with amyotrophic lateral sclerosis (ALS).

Previous page 1 2 3 4 5 6 7 8 Next page